Spero Therapeutics (SPRO) Free Cash Flow Growth (1y) (2017 - 2026)
Spero Therapeutics (SPRO) Free Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Spero Therapeutics |
129.74 Mn |
73.61 Mn |
- |
496.40% |
| Date | Value |
| Mar 31, 2026 |
496.40% |
| Dec 31, 2025 |
64.31% |
| Sep 30, 2025 |
36.50% |
| Jun 30, 2025 |
5.61% |
| Mar 31, 2025 |
-167.40% |
| Dec 31, 2024 |
-33.77% |
| Sep 30, 2024 |
-19.81% |
| Jun 30, 2024 |
-0.97% |
| Mar 31, 2024 |
146.20% |
| Dec 31, 2023 |
-139.33% |
| Sep 30, 2023 |
1,763.01% |
| Jun 30, 2023 |
19.40% |
| Mar 31, 2023 |
54.46% |
| Dec 31, 2022 |
262.88% |
| Sep 30, 2022 |
80.67% |
| Jun 30, 2022 |
-39.03% |
| Mar 31, 2022 |
-82.33% |
| Dec 31, 2021 |
-66.58% |
| Sep 30, 2021 |
76.77% |
| Jun 30, 2021 |
33.50% |